Otolith Labs

About Otolith Labs

Otolith Labs develops a noninvasive wearable device utilizing patented Vestibular Resonance Therapy (nVRT) technology to treat chronic vertigo, affecting over 11 million Americans. The device requires no surgery or complex fittings, providing a safe and effective alternative to traditional treatments.

```xml <problem> Chronic vertigo affects millions, significantly impacting their quality of life. Traditional treatments often involve surgery or complex fittings, presenting challenges for many patients seeking relief. </problem> <solution> Otolith Labs is developing a non-invasive wearable device that utilizes patented Vestibular Resonance Therapy (nVRT) to treat chronic vertigo. The headworn device is designed to be easy to use, requiring no surgery, advanced patient calibration, or complex fittings. Through clinical studies, the device has been tested on hundreds of subjects and is designed to be safe. The device aims to provide a safe and effective alternative for individuals seeking relief from chronic vertigo symptoms. </solution> <features> - Non-invasive Vestibular Resonance Therapy (nVRT) technology - Compact, headworn wearable design - No surgery, advanced patient calibration, or complex fittings required - Designed for safety, with testing on over 600 subjects - Intended to manage the symptoms of vertigo </features> <target_audience> The primary target audience includes individuals suffering from chronic vertigo, as well as healthcare providers seeking non-invasive treatment options for their patients. </target_audience> ```

What does Otolith Labs do?

Otolith Labs develops a noninvasive wearable device utilizing patented Vestibular Resonance Therapy (nVRT) technology to treat chronic vertigo, affecting over 11 million Americans. The device requires no surgery or complex fittings, providing a safe and effective alternative to traditional treatments.

Where is Otolith Labs located?

Otolith Labs is based in Newcastle West, Australia.

When was Otolith Labs founded?

Otolith Labs was founded in 2022.

How much funding has Otolith Labs raised?

Otolith Labs has raised $34.7M.

Who founded Otolith Labs?

Otolith Labs was founded by Jon Akers, Raphael Michel and Samuel Owen.

  • Jon Akers - CTO/Co-Founder
  • Raphael Michel - CEO
  • Samuel Owen - Founder/CEO
Location
Newcastle West, Australia
Founded
2022
Funding
$34.7M
Employees
21 employees
Major Investors
Morningside Venture Partners

Otolith Labs

10
Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

Otolith Labs develops a noninvasive wearable device utilizing patented Vestibular Resonance Therapy (nVRT) technology to treat chronic vertigo, affecting over 11 million Americans. The device requires no surgery or complex fittings, providing a safe and effective alternative to traditional treatments.

otolithlabs.com1K+
Founded 2022 – Newcastle West, Australia

Funding

No specific funding rounds found.

Total Funding

$34.7M

Backed by

Morningside Venture Partners

Team (20+)

Raphael Michel

CEO

Samuel Owen

Founder/CEO

Jon Akers

CTO/Co-Founder

Company Description

Problem

Chronic vertigo affects millions, significantly impacting their quality of life. Traditional treatments often involve surgery or complex fittings, presenting challenges for many patients seeking relief.

Solution

Otolith Labs is developing a non-invasive wearable device that utilizes patented Vestibular Resonance Therapy (nVRT) to treat chronic vertigo. The headworn device is designed to be easy to use, requiring no surgery, advanced patient calibration, or complex fittings. Through clinical studies, the device has been tested on hundreds of subjects and is designed to be safe. The device aims to provide a safe and effective alternative for individuals seeking relief from chronic vertigo symptoms.

Features

Non-invasive Vestibular Resonance Therapy (nVRT) technology

Compact, headworn wearable design

No surgery, advanced patient calibration, or complex fittings required

Designed for safety, with testing on over 600 subjects

Intended to manage the symptoms of vertigo

Target Audience

The primary target audience includes individuals suffering from chronic vertigo, as well as healthcare providers seeking non-invasive treatment options for their patients.

Sources:

1
This profile is AI-generated from web data and may contain inaccuracies. Want to correct or remove an entry? Owners can claim edits via their company email domain, and signed-in users can submit sourced suggestions.
Otolith Labs - Funding: $34.7M | StartupSeeker